logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Meredith McKean

Sarah Cannon Research Institute
H指数:22
被引数:3,069

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Linavonkibart和pembrolizumab在免疫检查点阻断耐药的晚期实体瘤中的应用: 1期试验

Nature Medicine
IF50
2026-01-130
OAAI
Timothy A. Yap; Randy F. Sweis; Ulka Vaishampayan; Deepak Kilari; Justin F. Gainor; Meredith McKean; Minal Barve; Ahmad A. Tarhini; Bruno Bockorny; Guru Sonpavde; David Park; Sunil Babu; Yawen Ju; Lan Liu; Susan Henry; Giridhar S. Tirucherai; Stephen DeWall; Mohammed Qatanani; Jing L. Marantz; Lu Gan
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors

一项关于modakafusp alfa单药及联合pembrolizumab治疗晚期或转移性实体瘤的Ib/II期研究

Frontiers in Oncology
IF3.3
2025-12-090
OAAI
David Gill; Charles L. Cowey; Gregory A. Daniels; David Sommerhalder; Raghad Abdul-Karim; John M. Kirkwood; Joanna Kolodney; Inderjit Mehmi; Rachel Roberts-Thomson; James Strauss; Sajeve Thomas; Eric Whitman; Yan Xing; Meredith McKean; Sabrina Collins; Cheryl Li; Gurpanna Saggu; Tian Chen; Shining Wang; Marina Lewis; Xavier Parot; Melissa Johnson
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors

HERTHENA-PanTumor01：一项关于帕托珠单抗德鲁克替康（HER3-DXd）在既往治疗过的晚期实体瘤中的II期研究

Future Oncology
IF2.6
2025-10-140
OAAI
Thomas Powles; Aarti Bhatia; Barbara Burtness; Takahiro Kogawa; Tomohiro Nishina; Izuma Nakayama; Christos Fountzilas; Dani R. Castillo; Meredith McKean; Funda Meric-Bernstam; Nicoletta Colombo; James W. Smithy; Jérome Fayette; Sunandana Chandra; David W. Sternberg; Fan Jin; Kendall Sullivan; Sue Yueh; Graham Clinthorne; Ariel E. Aguilo; Ragini Kudchadkar; Hidetoshi Hayashi
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

妊娠期晚期黑色素瘤：一项回顾性、多中心、基于注册研究的建议

eClinicalMedicine
IF10
2025-10-070
OAAI
Jessica S.W. Borgers; Douglas B. Johnson; Elisabeth Livingstone; Dirk Schadendorf; Elizabeth I. Buchbinder; Lauren E. Haydu; Laura Gohil; William A. Robinson; Inderjit Mehmi; Omid Hamid; Michelle Ferreira; April K.S. Salama; Florentia Dimitriou; Matteo S. Carlino; Georgina V. Long; Paolo A. Ascierto; Ester Simeone; Yana G. Najjar; Geke A.P. Hospers; Jacob Choi; Sunandana Chandra; Jeffrey D. Wayne; Carlos I.R. García; Wen Xu; Céleste Lebbé; Laetitia Da-Meda; Victoria Atkinson; Meredith Mckean; Andrea Forschner; Elliot A. Asare; Antonios Daletzakis; Jolyn S. Taylor; Frédéric Amant; Katy K. Tsai; Zeynep Eroglu; John B.A.G. Haanen; Isabella C. Glitza de Oliva
Proceedings of the seventh annual Women in Melanoma Conference

第七届黑色素瘤女性大会会议录

Therapeutic Advances in Medical Oncology
IF4.2
2025-06-140
OA
Yana G. Najjar; Marlana Orloff; Tara C. Mitchell; Tawnya L. Bowles; Allison Betof Warner; Kathryn Bollin; Sunandana Chandra; Justine V. Cohen; Zeynep Eroglu; Pauline Funchain; Elizabeth Gaughan; Isabella Glitza Oliva; Sherry Hsu; Siwen Hu-Lieskovan; Lucy Boyce Kennedy; Thach-Giao Truong; Meredith McKean; Janice Mehnert; Helen Moon; Katy K. Tsai; Melissa Wilson; Thuy Tran; Elizabeth I. Buchbinder; Leslie A. Fecher; Samantha Guild; Sapna P. Patel
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study

STARBOARD研究中，encorafenib联合binimetinib和pembrolizumab治疗BRAF V600突变型黑色素瘤成人的初步结果简明摘要。

FUTURE ONCOLOGY
IF2.6
2025-05-060
OA
Dudnichenko, Oleksandr; Penkov, Konstantin; McKean, Meredith; Mandala, Mario; Kukushkina, Mariia; Panella, Timothy; Csoszi, Tibor; Gerletti, Paola; Thakur, Mahgull; Poll, Anna; di Pietro, Alessandra; Schadendorf, Dirk
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

一线encorafenib联合binimetinib和pembrolizumab治疗晚期BRAF V600-mutant黑色素瘤: 随机III期STARBOARD研究的安全导入结果

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
PRE
Dudnichenko, Oleksandr; Penkov, Konstantin; Mckean, Meredith; Mandala, Mario; Kukushkina, Mariia; Panella, Timothy; Csoszi, Tibor; Gerletti, Paola; Thakur, Mahgull; Polli, Anna; di Pietro, Alessandra; Schadendorf, Dirk
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023
PIGMENT CELL & MELANOMA RESEARCH
IF2.6
2024-10-090
OA
Seedor, Rino S.; Aplin, Andrew E.; Bertolotto, Corine; Carvajal, Richard D.; Deacon, Nigel; Doble, Katie; Hamid, Omid; Haq, Rizwan; Kadosh, Miriam; Khan, Shaheer; Kraska, Jacqueline; Lutzky, Jose; McKean, Meredith; Montazeri, Kamaneh; Moser, Justin; Onken, Michael; Orloff, Marlana; Sacco, Joseph J.; Smalley, Keiran; Selig, Sara M.
IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma

IDE196（darovasertib）联合crizotinib与研究者选择的治疗方案作为HLA-A2阴性转移性眼黑色素瘤的一线治疗

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Butler, M. O.; Weight, R.; Haq, R.; Javed, A.; Chandana, S.; Chmielowski, B.; Dummer, R.; Carlino, M. S.; Mckean, M.; Moser, J.; Chandrasekaran, S.; Khan, S.; Kim, K. B.; Lutzky, J.; Shackleton, M.; Atkinson, V. G.; Beaupre, D.; Cole, G. W., Jr.; Patel, H.; Orloff, M.
A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors

一项评估exarafenib（一种选择性泛RAF抑制剂）联合binimetinib治疗NRAS突变（NRASMut）黑色素瘤（Mel）和BRAF变异实体瘤的I期临床试验。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Cassier, P.; Mehnert, J. M.; Kim, R.; Chmielowski, B.; Millward, M.; Perez, C. A.; Gonzalez Cao, M.; Gambardella, V.; Mckean, M.; Brose, M. S.; Xing, Y.; Long, G. V.; Kelly, A.; Lee, G.; Severson, P.; Williams, R.; Marqueste, C. Gaudy
Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors

接受自行车毒素偶联物（BTCs）BT8009或BT5528单药治疗的晚期实体瘤患者中出现的周围神经病变（PN）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Doger de Speville, B.; Mckean, M.; Baldini, C.; Italiano, A.; Reig Torras, O.; Fontana, E.; Verlingue, L.; Bashir, B.; Wang, J. S.; DeMars, L.; Josephs, K.; Feliu, W. I. Ortuzar; De, A.; Gu, X.; Xu, C.; Li, M.; Carter, L.
A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations

一项I期、首次人体、剂量递增和扩展研究，评估口服泛RAF/MEK分子胶NST-628在携带RAS-MAPK通路异常的实体瘤受试者中的效果。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Lemech, C.; Luke, J. J.; Falchook, G. S.; Mckean, M.; Kichenadasse, G.; Teng, C.; Vandross, A. L.; Salkeni, M. A.; Atkinson, V. G.; Liu, J. J.; Kennedy, A. M.; Clark, J.; Ryan, M.; Schmidt-Kittler, O.; Steinhubel, D.; Wages, D.; Komarnitsky, P.; Puzanov, I.
Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

mRNA-4157（V940）联合pembrolizumab或pembrolizumab单药治疗在切除的黑素瘤中复发的机制：来自mRNA-4157-P201（KEYNOTE-942）试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Sullivan, R. J.; Lu, M.; Koppolu, S.; Weber, J. S.; Carlino, M. S.; Khattak, M. A.; Ansstas, G.; Taylor, M. H.; Mckean, M.; Long, G. V.; Faries, M. B.; Luke, J. J.; Sehgal, V.; Rao, A.; Mao, H.; Guo, J.; Brown, M.; Meehan, R.; Feldman, I.; Srinivasan, L.
EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study

EphA2靶向环形分子毒素偶联物（BTC）BT5528在晚期实体瘤患者（pts）中的I/II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fontana, E.; Wang, J. S.; Mckean, M.; Aljumaily, R.; Machiels, J-P.; Doger de Speville, B.; Vieito, M.; Carter, L.; Prenen, H.; Falchook, G. S.; Greystoke, A.; Feliu, W. I. Ortuzar; De, A.; Gu, X.; Li, M.; de Rienzo, A.; Bashir, B.
HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors

HERTHENA-PanTumor01：一项关于HER3-DXd在转移性实体瘤中的全球性II期临床试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Powles, T. B.; Bhatia, A. K.; Burtness, B.; Kogawa, T.; Nishina, T.; Nakayama, I.; Fountzilas, C.; Castillo, D. R.; Mckean, M.; Meric-Bernstam, F.; Colombo, N.; Smithy, J. W.; Fayette, J.; Chandra, S.; Sternberg, D. W.; Sullivan, K. H.; Yueh, S.; Clinthorne, G.; Kudchadkar, R.; Hayashi, H.
First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors

首次人体I期试验：评估溶瘤单纯疱疹病毒ONCR-177单药或联合帕博利珠单抗治疗晚期实体瘤的效果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Gaspar, C. Fava; Park, J. C.; Falchook, G. S.; Wesolowski, R.; Soliman, H.; Ott, P. A.; Bilen, M. A.; Mckean, M.; Villaflor, V.; Chow, L. Q. M.; Yanez, A.; Dupont, C.; Shepherd, J.; Cheema, T.; Goldberg, J. M.; Puzanov, I.; Spreafico, A.

研究方向

暂未获取到该数据
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.6万
R
Ryan J. Sullivan
H 指数:90论文数:1,082被引数:4.4万
D
Dirk Schadendorf
H 指数:182论文数:2,386被引数:22.1万
G
Georgina V. Long
H 指数:169论文数:1,833被引数:17.2万
E
Elizabeth I. Buchbinder
H 指数:38论文数:258被引数:1.3万
J
Jason J. Luke
H 指数:63论文数:811被引数:2.2万
E
Elisa Fontana
H 指数:20论文数:216被引数:1,874
M
Matteo S. Carlino
H 指数:82论文数:667被引数:5.6万
N
Nehal J. Lakhani
H 指数:28论文数:283被引数:4,385
P
Paolo A. Ascierto
H 指数:126论文数:1,662被引数:10.8万